Brilanta was approved by the U.S. Food and Drug Administration (FDA) for its efficacy in reducing the risk of stroke in patients with acute-ischemic stroke based on the Phase 3 THALES Trial. Compared to aspirin alone, when taken with Brilanta there was a clinically significant 17% reduction in death from a stroke, the leading cause of disability and death worldwide. Among other approvals Astrazenca has received is the PARP inhibitor Lynparza and Farxiga.
Read more here.
More on: News Regulatory